Clinical trial · Interventional
Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer
NCT01541358CI-TRIAL-00028092terminatedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low accrual and no funding
Summary
Brief summary (as posted)
This clinical trial studies fluorine F-18 sodium fluoride positron emission tomography (PET)/computed tomography (CT) in diagnosing bone tumors in patients with cancer. Diagnostic procedures, such as fluorine F-18 sodium fluoride PET/CT, may help find and diagnose bone cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Cancer | Malignant Bone Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| fluorine F 18 sodium fluoride | Radiation | — | UNRESOLVED |
| positron emission tomography/computed tomography | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (fluorine F 18 sodium fluoride PET/CT)
- description
- Patients undergo fluorine F 18 sodium fluoride PET/CT scan.
- interventionNames
- Radiation: fluorine F 18 sodium fluoride
- Procedure: positron emission tomography/computed tomography
Primary outcomes (1)
- measure
- Total Number of Lesions Identified by F-18 NaF PET/CT in Patients With Suspected Skeletal Malignancy
- timeFrame
- an estimated average of 2 hours
- description
- F-18 NaF is a positron emission tomography (PET) bone imaging agent that targets changes in the bone. The fluoride ions are taken up in areas of the bone that have increased bone remodeling (bone repair) and increased blood flow, which is indicative of diseases such as cancer.
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients referred for evaluation of suspected skeletal cancer * Patients must understand and voluntarily sign an informed consent form after the contents have been fully explained to them Exclusion Criteria: * Patients who cannot complete a PET/CT scan * Pregnant women * Healthy volunteers
References
Publications (0)
Data not yet available
No reference posted for this study.